A randomized controlled trial on acupuncture treatment of diarrheal-predominant irritable bowel syndrome

注册号:

Registration number:

ITMCTR2100004642

最近更新日期:

Date of Last Refreshed on:

2021-03-26

注册时间:

Date of Registration:

2021-03-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针灸治疗腹泻型肠易激综合征的随机对照临床研究

Public title:

A randomized controlled trial on acupuncture treatment of diarrheal-predominant irritable bowel syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针灸治疗腹泻型肠易激综合征的随机对照临床研究

Scientific title:

A randomized controlled trial on acupuncture treatment of diarrheal-predominant irritable bowel syndrome

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100044762 ; ChiMCTR2100004642

申请注册联系人:

齐翎羽

研究负责人:

刘存志

Applicant:

Qi Lingyu

Study leader:

Liu Cunzhi

申请注册联系人电话:

Applicant telephone:

+86 18265615112

研究负责人电话:

Study leader's telephone:

+86 10 53912201

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qly66love@163.com

研究负责人电子邮件:

Study leader's E-mail:

lcz_tg@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 North Third Ring Road East, Chaoyang District, Beijing.

Study leader's address:

11 North Third Ring Road East, Chaoyang District, Beijing.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学针灸推拿学院

Applicant's institution:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020BZHYLL0801

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/12/16 0:00:00

伦理委员会联系人:

秦灵灵

Contact Name of the ethic committee:

Qin Lingling

伦理委员会联系地址:

北京市朝阳区北三环东路11号

Contact Address of the ethic committee:

11 North Third Ring Road East, Chaoyang District, Beijing, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 53911431

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学

Primary sponsor:

Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市朝阳区北三环东路11号

Primary sponsor's address:

11 North Third Ring Road East, Chaoyang District, Beijing.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学

具体地址:

朝阳区北三环东路11号

Institution
hospital:

Beijing University of Chinese Medicine

Address:

11 North Third Ring Road East, Chaoyang District.

经费或物资来源:

国家重点研发计划中医药现代化研究重点专项(项目编号:2019YFC1712100)

Source(s) of funding:

National Key R&D Program of China (2019YFC1712100)

研究疾病:

肠易激综合征

研究疾病代码:

Target disease:

Irritable bowel syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评价针灸治疗肠易激综合征的有效性和安全性。

Objectives of Study:

To evaluate the efficacy and safety of acupuncture in the treatment of irritable bowel syndrome.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄18-75岁之间(包括18岁和75岁),男女不限; 2.符合罗马Ⅳ腹泻型肠易激综合征亚型诊断标准; 3.近2周每日排便日记报告为Bristol粪便性状6型或7型至少4天且Bristol粪便性状1型或2型少于4天;近1周平均每日腹痛评分≥3分; 4.过去6个月内未接受针灸治疗; 5.治疗前2周内未服用抗抑郁药物及对肠易激综合征症状有治疗作用的药物,包括中药或中成药、止泻剂、解痉药、肠道抗生素、益生菌制剂等。

Inclusion criteria

1. Aged between 18 and 75 years (no gender limitation); 2. Meets the diagnostic criteria of diarrheal-predominant irritable bowel syndrome (IBS-D); 3. Type 6 or 7 of the Bristol Stool Form Scale appeared for at least 4 days and type 1 or 2 appeared for less than 4 days in last 2 weeks; The average score of daily abdominal pain was >= 3 in the last week; 4. No treatment of acupuncture in the last 6 months; 5. No use of antidepressant or IBS medication within 2 weeks before treatment, including traditional Chinese medicine (TCM) or proprietary Chinese medicine, antidiarrheal, antispasmodic, intestinal antibiotics, probiotics and so on.

排除标准:

1.便秘型IBS/混合型IBS,炎性肠病/显微镜下结肠炎/乳糜泻病史/克罗恩病等器质性肠病; 2.糖尿病、甲状腺功能异常; 3.严重的急/慢性器质性疾病及肾病或肝病; 4.既往腹部手术史(超过3个月的阑尾手术、痔疮手术、息肉手术患者可以纳入); 5.孕期或哺乳期; 6.酒精、药物滥用史; 7.参加其他临床试验的患者等。

Exclusion criteria:

1.Patients with the following diseases: inflammatory bowel disease, microscopic colitis, celiac disease, Crohn's disease and other organic bowel diseases; 2.Diabetes mellitus and abnormal thyroid function; 3.Severe acute or chronic organic diseases, kidney or liver diseases; 4.History of abdominal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed.); 5.Pregnancy or lactation; 6.History of alcohol and drug abuse; 7.Participating in other clinical trials.

研究实施时间:

Study execute time:

From 2021-04-01

To      2022-04-30

征募观察对象时间:

Recruiting time:

From 2021-04-01

To      2021-11-30

干预措施:

Interventions:

组别:

假针组

样本量:

140

Group:

Sham acupuncture group

Sample size:

干预措施:

针刺非经非穴点,治疗6周,共计15次

干预措施代码:

Intervention:

Acupuncture non-acupoints for 6 weeks, a total of 15 times

Intervention code:

组别:

针刺组

样本量:

140

Group:

True acupuncture group

Sample size:

干预措施:

针刺特定穴,治疗6周,共计15次

干预措施代码:

Intervention:

Acupuncture specific acupoints for 6 weeks, a total of 15 times

Intervention code:

样本总量 Total sample size : 280

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三甲

Institution/hospital:

First Teaching Hospital of Tianjin University of TCM

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东中医药大学附属医院

单位级别:

三甲

Institution/hospital:

The Affiliated Hospital of Shandong University of TCM

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

单位级别:

三甲医院

Institution/hospital:

Teaching Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

单位级别:

三甲

Institution/hospital:

Dongfang Hospital, Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北中医学院附属医院

单位级别:

三甲

Institution/hospital:

The Affiliated Hospital of Hebei University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

有效应答率

指标类型:

主要指标

Outcome:

Effective response rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠易激综合征整体症状问卷

指标类型:

次要指标

Outcome:

IBS symptom severity scale, IBS-SSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑磁共振成像

指标类型:

附加指标

Outcome:

brain magenetic resonance imaging

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

排便频率

指标类型:

次要指标

Outcome:

defecation frequency

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹胀症状

指标类型:

次要指标

Outcome:

Symptoms of bloating

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

副作用指标

Outcome:

Adverse event rate

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

其他时间点的有效应答率

指标类型:

次要指标

Outcome:

Effective response rate at other time points

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹痛症状

指标类型:

次要指标

Outcome:

Symptoms of abdominal pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠易激综合征专用生活质量测试问卷

指标类型:

次要指标

Outcome:

Quality of life questionnaire, IBS-QOL

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

盲法及可信度评价

指标类型:

附加指标

Outcome:

Blind method and credibility evaluation

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠易激综合征症状的充分缓解

指标类型:

次要指标

Outcome:

IBS-AR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者健康问卷抑郁量表

指标类型:

次要指标

Outcome:

Patient Health Questionnaire Depression Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用区组随机方法通过统计学软件生成随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

This trial will use central block randomization method produced by statistical analysis software.

盲法:

本试验对受试者、数据收集/录入者和统计人员设置盲法。

Blinding:

Patients, outcome assessor and statistician will be blinded to the assignments.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内,通过中国临床试验注册中心的ResMan平台进行原始数据的共享(http://www.medresman.org.cn.)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the trial complete, we will share IPD based on the ResMan platform (http://www.medresman.org.cn.)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过电子采集和管理系统记录数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The records of metadata are recorded through Electronic Data Capture.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above